Dr. Steinbach’s research is focused on gastrointestinal cancer prevention, including genetic and clinical predisposition, chemoprevention, and early detection. The work is based on multidisciplinary and inter-institutional collaborations. His recent collaborative studies investigated the role of aspirin in the prevention of colorectal adenomatous polyps in persons with previous colorectal tumors and the effect of cyclooxygenase-2 inhibition on colorectal adenomatous polyps in patients with FAP (an inherited predisposition to colorectal adenomas). The latter was the first clinical trial to investigate the effect of COX-2 inhibition on a human tumor. Demonstration of efficacy on adenomatous polyps in FAP provided support for initiating trials of COX-2 inhibition for the control of sporadic colon tumors and other tumors that express COX-2.